Connect with us

INDUSTRIAL HEMP

AbbVie Inc (NYSE:ABBV) Reports Positive Phase III Extension Study Report For Investigational Oral Treatment Elagolix

Published

on

AbbVie Inc (NYSE:ABBV) a research and development based international biopharmaceutical firm in cooperation with Neurocrine Biosciences, Inc. (NASDAQ:NBIX), reported detailed data from two replicate Phase III extension trials assessing the long-term safety and efficacy of elagolix, an investigational, orally administered GnRH antagonist, being assessed for the management of endometriosis with related pain.

In the extension trials, elagolix showed sustained decline in average monthly non-menstrual pelvic pain and menstrual pelvic pain in females through the 1-year treatment period. The tolerability and safety of elagolix was consistent with the projected effects of lowered estradiol levels and no new safety issues were identified with elagolix application for the 12-month treatment period. This data, and other additional abstracts, were showcased at the ASRM in San Antonio.

The details

Eric Surrey, M.D., expressed that endometriosis is a painful and chronic disease. The data showcased are positive for patients and are steady with previous data that showcase elagolix has the prospect to be a vital non-surgical treatment alternative for women with the most prevalent indications of endometriosis.

The goal of the extension trials was to assess the long-term efficacy and safety of elagolix for the management of endometriosis with related pain. The efficacy objectives of the pivotal trials were the proportion of responders depending on the average monthly non-menstrual pelvic pain and menstrual pain scores, as known by the Daily Evaluation of Endometriosis Pain scale. The reductions in non-menstrual pelvic pain and dysmenorrhea following six months of elagolix therapy were maintained over another six months of treatment across both extension trials for both 150 mg QD and 200 mg BID doses.

Over 50% of women were responders for non-menstrual pelvic pain and dysmenorrhea at both doses. The responder rate for dyspareunia after one year was more with the 200 mg BID dose as compared to the 150 mg QD dose, which showcases a dose-dependent effect similar to the impact noted in pivotal trials.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized1 day ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health2 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business2 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business2 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business2 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP2 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP2 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP2 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

INDUSTRIAL HEMP2 weeks ago

Kush Bottles Inc (OTCMKTS:KSHB)’ Q1 Results For Fiscal Year 2018 Released

Leading supplier and service provider to the cannabis sector, Kush Bottles Inc (OTCMKTS:KSHB), has released financial results for 2018’s first...

INDUSTRIAL HEMP2 weeks ago

Wanderport Corp. (OTCMKTS:WDRP) Will Accept The Use Of Bitcoin In Its E-Commerce Store

Wanderport Corp. (OTCMKTS:WDRP) has made good its promise of allowing full access to the Company’s full suite of products. The...

Advertisement
Advertisement